VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from the European Institute of Oncology in Milan. After his talk at the St Gallen breast cancer conference he discussed criteria for individualizing optimal endocrine adjuvant treatments with Oncology Times reporter Sarah Maxwell.
You may also like...
Prostate cancer screening: French study finds more harm than good from PSA testing 19 Nov, 2013 Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer 8 Jun, 2018 Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia 19 Dec, 2013 Breast cancer: less radiotherapy in fewer hospital visits is just as good for preventing relapse 11 Dec, 2012
- Previous story Genetic Tests for Breast Cancer Late Recurrence Risk—Not Yet Ready for Prime Time
- Next story Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014